The goal of this clinical trial is to learn if veverimer will reduce urinary net acid excretion leading to reduced bone resorption in healthy adults with osteopenia. The main questions it aims to answer are: * How much does each dose of veverimer (vs. placebo) reduce 24-hr urinary net acid excretion. * Describe the safety of veverimer based on changes in serum bicarbonate and potassium. * Assess the changes in bone resorption. * Assess the changes in bone formation. * Explore the effect of veverimer on physical performance. Participants will: * Take veverimer or placebo every day or every other day for 8 weeks * Visit the clinic a total of 8 times (including screening) for checkups and testing * Keep a medication diary tracking each day they take the study drug
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
60
8 weeks of taking 9 grams of veverimer (a powder mixed into water) daily
8 weeks of taking 9 grams of veverimer (a powder mixed into water) every other day
8 weeks taking 9 grams microcrystalline cellulose (powdered mixed into water) daily or every other day
Tufts Medical Center
Boston, Massachusetts, United States
RECRUITING24-hr urinary net acid excretion
Time frame: measured at screening, week 2, week 8 and week 8 +1day
Serum bicarbonate level
Time frame: measured at screening, week 0, week 1, week 2, week 4, week 8
Serum potassium level
Time frame: measured at screening, week 0, week 1, week 2, week 4, week 8
Serum C-telopeptide level
Time frame: measured at week 0, week 2, week 8
Serum procollagen type 1 N-propeptide level
Time frame: measured at week 0 and week 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.